Development of Single Domain Antibodies for Diagnosis and Treatment of Naturally Occurring Canine Lymphoma: An Animal Model for Human Non-Hodgkin Lymphoma

摘要

Lymphomas are among the most common malignant tumors of dogs. It accounts for approximately 7%-24% of all canine neoplasia and 83% of all canine hematopoietic malignancies. As a systemic disease, canine lymphoma requires prompt systemic chemotherapy to achieve remission and prolonged survival. The CHOP based protocols remain the most effective therapy, yielding complete responses in over 80% of dogs. Unfortunately, the cure is rarely achieved and the median survival time is 6 to 12 months, depending on the protocol chosen. Canine lymphoma and human non-Hodgkin's lymphoma share many histopathological, molecular, genetic and clinical features, making the canine species an excellent non-rodent animal model for the study of lymphoma, including research on new therapeutic agents and approaches.